CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani; Ian W. Flinn; Leslie Popplewell; Andres Forero; Nancy L. Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann S. LaCasce; Graham P. Collins; Thu Ha Tran; Judith Lynn; James Y. Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L. Weissman; Chris H. Takimoto; Mark P. Chao; Sonali M. Smith

doi:10.1056/nejmoa1807315

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin's lymphoma cells by enhancing macrophage-mediated antibody-dependent cellular phagocytosis. This combination was evaluated clinically.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Advani et al. (2018) studied this question.

synapsesocial.com/papers/6902277f82e6c353f8456d0a https://doi.org/10.1056/nejmoa1807315

View Full Paper

Ask AI

Bookmark

Share

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading